(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Quince Therapeutics's earnings in 2025 is -$56,979,000.On average, 8 Wall Street analysts forecast QNCX's earnings for 2025 to be -$63,031,447, with the lowest QNCX earnings forecast at -$63,298,718, and the highest QNCX earnings forecast at -$60,219,531. On average, 8 Wall Street analysts forecast QNCX's earnings for 2026 to be -$39,561,699, with the lowest QNCX earnings forecast at -$67,825,623, and the highest QNCX earnings forecast at -$6,431,212.
In 2027, QNCX is forecast to generate -$32,562,535 in earnings, with the lowest earnings forecast at -$67,118,468 and the highest earnings forecast at -$1,753,967.